5 days ago
Lymphoma Highlights From ASCO 2025
Lymphoma highlights from ASCO 2025 are reported by Dr Christopher Flowers from MD Anderson Cancer Center in Houston, Texas.
Dr Flowers first reviews a phase 1 study of KITE-363, an anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed or refractory (R/R) B-cell lymphoma. There were no dose-limiting toxicities (a primary endpoint). Grade 3 adverse events occurred in 76% of patients. Patients with primary refractory disease had an overall response rate (ORR) of 80% and a favorable complete response (CR) rate of 67%.
Dr Flowers also examines the phase 2/3 clinical trial of zilovertamab vedotin plus standard of care in R/R large B-cell lymphoma. The combination showed meaningful efficacy in ORR rates and CR.
Dr Flowers next reviews a phase 2 dose-finding study on AFM13 (CD30/CD16A therapy) plus cord blood allogeneic NK cells. In 24 heavily pretreated patients who received varying doses of both agents, no dose-limiting toxicity was identified and there were no fatal combinations of adverse events. Efficacy and safety extended across several dosages. The ORR was 88% and the CR was 58%.
Finally, Dr Flowers reviews early data on multivirus-specific T cells to enhance bispecific antibodies in lymphoma. The T cells, which were enhanced against EBV, CMV, BK virus, and adenovirus, demonstrated ability to kill lymphoma cells in vitro, which may prove a future strategy to enhance tumor activity of bispecific antibodies.
